HEERLEN, Netherlands, May 7, 2020 /PRNewswire/ --
-- DSM reports a solid quarter
-- Early actions on COVID-19 ensured continuity of operations and supply to
-- Group sales and Adjusted EBITDA stable - Nutrition: sales +4%, organic
sales +2%, Adjusted EBITDA +3 - Materials: sales -8%, volumes -6%,
Adjusted EBITDA -7%
-- Adjusted net profit up 8% to EUR216m. Net profit: EUR168m
-- Strong Adjusted Net Operating Free Cash Flow of EUR151m, up 152%
-- Outlook 2020: DSM expects Nutrition to deliver at least a mid-single
digit increase in Adjusted EBITDA, but given current limited visibility
in Materials the overall earnings outlook is suspended at this time
Key figures and indicators
in EUR million Q1 2020
Sales 2,293 2,292 0% 1% -3% 1% 1%
Nutrition 1,575 1,517 4% 5% -3% 1% 1%
Materials 660 717 -8% -6% -4% 1% 1%
Adjusted EBITDA 423 424 0%
Nutrition 324 316 3%
Materials 118 127 -7%
Innovation 5 6
Corporate -24 -25
EBITDA 358 416
Adjusted EBITDA margin 18.4% 18.5%
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: "COVID-19 has led to unprecedented global challenges. We took very early actions and focused on ensuring the health and safety of our employees and partners, keeping our operations running and serving customers and society with our essential products. We are proud of how our people are responding to the new challenges and are also supporting the communities around them in so many different ways.
We saw good underlying business conditions in Nutrition, with momentum increasing through the quarter, and with an overall small increase in demand from COVID-19. At the same time, trading conditions in Materials deteriorated rapidly at the end of Q1 as customers' operations were impacted by COVID-19 restrictions, especially in Europe and North America.
While these are uncertain times, we are taking all necessary actions to address recent challenges in end markets. We remain well-positioned to manage near-term developments with a growing Nutrition business and a strong financial position. We stay focused on our long-term strategy to deliver above-market growth, pursuing our innovation programs, and growth initiatives, supported by the execution of our self-help actions."
There is considerable uncertainty as to how the COVID-19 pandemic will develop and what will be the global ramifications. Within this context, DSM expects Nutrition to deliver at least a mid-single digit increase in Adjusted EBITDA for 2020 compared to prior year, but given current limited visibility in Materials it feels prudent not to express an overall earnings outlook at this time.
DSM responded quickly to the COVID-19 outbreak, initiating very strict protocols to increase already stringent hygiene and safety precautions throughout its facilities and supply chain worldwide. Through these measures DSM is protecting the well-being of its employees and partners while keeping production facilities running. Given that many of its products and solutions are considered vital by national governments, DSM's facilities are typically permitted to keep operating and are less impacted by logistics restrictions.
DSM estimates that Nutrition overall saw a slight increase of about 1% on its Q1 sales from COVID-19. Materials saw a negative impact of about 7% of sales with the main effect at the end of the quarter as customers' operations were severely impacted by COVID-19 measures especially in Europe and North America. As these measures continue into Q2, DSM is taking actions in Materials to limit capital expenditure and operating costs to protect its earnings and cashflow without compromising the medium- and long-term potential of its businesses.
In addition, DSM is also supporting the fight against the pandemic. DSM is applying scientific know-how and its resources through a variety of global and local initiatives including helping to improve personal protective equipment designs, producing critical disinfectants and equipment for hospitals, leading a consortium to produce face masks, distributing immunity-optimizing vitamins to healthcare workers, and more as shown in the sustainability highlights.
DSM continues to benefit from a strong balance sheet and available liquidity, with Q1 2020 Net Debt to EBITDA of 0.8x, strong cash generation and committed, undrawn revolving credit facilities of EUR1.5 billion. These facilities, comprised of a EUR1 billion revolving credit facility maturing in 2025 and EUR500 million new revolving credit facilities concluded recently, are not subject to any financial covenants or a MAC clause. Additionally, the company has no bond maturities in 2020 and 2021. DSM remains committed to maintaining a strong investment-grade credit profile.
Reflecting the strength of its financial position, DSM remains committed to its capital allocation policy. DSM will continue to reinvest capital into driving organic growth via disciplined capex and is committed to pursue its existing policy of distributing stable, preferably rising, dividends to its shareholders. DSM's dividend proposal for approval at its AGM on 8 May 2020 remains EUR2.40 per share, as communicated in February 2020, up 4% versus 2019.
Concurrently, having bought back EUR745 million shares as at Q1 2020, DSM believes it prudent to pause the remainder of its EUR1 billion share buy-back program, launched in 2019, as a precaution given the current environment.
On 1 April 2020 DSM completed the acquisition of Glycom, as announced on 21 February 2020, for an enterprise value of EUR765 million, which will be incorporated in the results as of Q2 2020. Glycom is the world's leading supplier of Human Milk Oligosaccharides (HMO).
Note to the editors: for the full text of the see enclosed pdf or click here> [https://www.dsm.com/corporate/news/news-archive/2020/19-20-dsm-q1-2020-results.html]
8 May 2020 Annual General Meeting of
4 August 2020 Publication of the half year
results of 2020
3 November 2020 Publication of the results of the
first nine months of 2020
4 November 2020
Capital Markets Day
Today DSM will hold a conference call for media at 08:00 CET and a conference call for investors and analysts at 09:00 CET. Details on how to access these calls can be found on the DSM website, www.dsm.com [http://www.dsm.com/].
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about EUR10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com [http://www.dsm.com/].
Forward Looking Statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Logo - https://mma.prnewswire.com/media/657851/DSM_Logo.jpg [https://mma.prnewswire.com/media/657851/DSM_Logo.jpg]
CONTACT: Investor Relations, Dave Huizing, t. +31 (0) 45 578 2864, e. email@example.com, Media Relations, Lieke de Jong, t. +31 (0) 45 578 2420, e. firstname.lastname@example.org
Web site: http://www.dsm.com//